Report on the use of non‐clinical studies in the regulatory evaluation of oncology drugs

Non‐clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs.

[1]  Michel Sadelain,et al.  The journey from discoveries in fundamental immunology to cancer immunotherapy. , 2015, Cancer cell.

[2]  V. Gandhi,et al.  Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma , 2015, Clinical Cancer Research.

[3]  G. Demetri,et al.  Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy , 2014, BMC Cancer.

[4]  M. Poupon,et al.  Patient-derived tumour xenografts as models for breast cancer drug development , 2014, Current opinion in oncology.

[5]  K. Kumamoto,et al.  A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. , 2014, Carcinogenesis.

[6]  C. V. van Deurzen,et al.  A mouse model for endometrioid ovarian cancer arising from the distal oviduct , 2014, International journal of cancer.

[7]  Matthias Dobbelstein,et al.  Targeting tumour-supportive cellular machineries in anticancer drug development , 2014, Nature Reviews Drug Discovery.

[8]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[9]  G. Hannon,et al.  Patient-derived tumor xenografts: transforming clinical samples into mouse models. , 2013, Cancer research.

[10]  Lesley A. Mathews,et al.  Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. , 2013, Cancer cell.

[11]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[12]  H. Saya,et al.  Complexity of cancer stem cells , 2013, International journal of cancer.

[13]  Joseph M. Negri,et al.  The role of tumour–stromal interactions in modifying drug response: challenges and opportunities , 2013, Nature Reviews Drug Discovery.

[14]  Y. Totoki,et al.  Mouse Model for ROS1-Rearranged Lung Cancer , 2013, PloS one.

[15]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[16]  P. Chuang,et al.  Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis , 2012, Proceedings of the National Academy of Sciences.

[17]  C. Pritchard,et al.  The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. , 2012, Genes & development.

[18]  M. Yi,et al.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. , 2012, Cancer research.

[19]  T. Schumacher,et al.  Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma , 2012, Oncoimmunology.

[20]  E. Aronica,et al.  GFAP-Cre-Mediated Transgenic Activation of Bmi1 Results in Pituitary Tumors , 2012, PloS one.

[21]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[22]  F. Gärtner,et al.  Canine tumors: a spontaneous animal model of human carcinogenesis. , 2012, Translational research : the journal of laboratory and clinical medicine.

[23]  M. Nogawa,et al.  Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1. , 2012, Anticancer research.

[24]  S. Durinck,et al.  Conditional activation of Pik3caH1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations , 2012, Oncogene.

[25]  S. Kopetz,et al.  Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. , 2012, Cancer research.

[26]  S. Egan,et al.  Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. , 2011, Cancer research.

[27]  Francesca Zappacosta,et al.  GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition , 2011, Clinical Cancer Research.

[28]  P. Jänne,et al.  Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. , 2010, Cancer research.

[29]  S. Dry,et al.  PTEN loss accelerates KrasG12D-induced pancreatic cancer development. , 2010, Cancer research.

[30]  T. Ried,et al.  Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency , 2010, Oncogene.

[31]  S. Sleijfer,et al.  (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. , 2010, The oncologist.

[32]  A. Ashworth,et al.  Brca2 and Trp53 Deficiency Cooperate in the Progression of Mouse Prostate Tumourigenesis , 2010, PLoS genetics.

[33]  J. Qin,et al.  The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression , 2010, Oncogene.

[34]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[35]  N. Dhomen,et al.  Inducible expression of V600EBraf using tyrosinase‐driven Cre recombinase results in embryonic lethality , 2010, Pigment cell & melanoma research.

[36]  Umar Mahmood,et al.  Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment , 2010, Proceedings of the National Academy of Sciences.

[37]  Metin N. Gurcan,et al.  Pten in Stromal Fibroblasts Suppresses Mammary Epithelial Tumors , 2009, Nature.

[38]  B. Spencer‐Dene,et al.  The Apc 1322T mouse develops severe polyposis associated with submaximal nuclear beta-catenin expression. , 2009, Gastroenterology.

[39]  W. Schulz-Schaeffer,et al.  Time-point and dosage of gene inactivation determine the tumor spectrum in conditional Ptch knockouts. , 2009, Carcinogenesis.

[40]  Y. Ishikawa,et al.  A mouse model for EML4-ALK-positive lung cancer , 2008, Proceedings of the National Academy of Sciences.

[41]  Andreas Trumpp,et al.  Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation , 2008, Nature Genetics.

[42]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.

[43]  Robert Machold,et al.  Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. , 2008, Cancer cell.

[44]  S. Dey,et al.  Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. , 2008, Cancer research.

[45]  C. Der.  Faculty Opinions recommendation of Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. , 2008 .

[46]  A. Sweet-Cordero,et al.  Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon , 2008, Nature Genetics.

[47]  R. Cardiff,et al.  Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. , 2008, Cancer research.

[48]  M. Paoloni,et al.  Translation of new cancer treatments from pet dogs to humans , 2008, Nature Reviews Cancer.

[49]  R. Jaenisch,et al.  Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. , 2007, Genes & development.

[50]  A. Ashworth,et al.  A mouse model of basal‐like breast carcinoma with metaplastic elements , 2007, The Journal of pathology.

[51]  M. Serrano,et al.  A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. , 2007, Genes & development.

[52]  Sungjoon Kim,et al.  Ba/F3 cells and their use in kinase drug discovery , 2007, Current opinion in oncology.

[53]  H. Moses,et al.  Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. , 2006, Genes & development.

[54]  Daniel J. Freeman,et al.  Genetic background controls tumor development in PTEN-deficient mice. , 2006, Cancer research.

[55]  Ralph Weissleder,et al.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[56]  G. Kay,et al.  Melanocytes in conditional Rb-/- mice are normal in vivo but exhibit proliferation and pigmentation defects in vitro. , 2005, Pigment cell research.

[57]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[58]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[59]  M. Giovannini,et al.  Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[60]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[61]  M. Hande,et al.  Collaboration of Brca1 and Chk2 in tumorigenesis. , 2004, Genes & development.

[62]  H. Koeppen,et al.  HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice , 2004, Clinical Cancer Research.

[63]  Takashi Tsuruo,et al.  Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal , 2003, Cancer science.

[64]  D. Neuberg,et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.

[65]  K. Palczewski,et al.  Vaccination with recoverin, a cancer‐associated retinopathy antigen, induces autoimmune retinal dysfunction and tumor cell regression in mice , 2002, European journal of immunology.

[66]  A. Berns,et al.  PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. , 2002, Development.

[67]  Laurence H. Hurley,et al.  DNA and its associated processes as targets for cancer therapy , 2002, Nature Reviews Cancer.

[68]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[69]  D. Brown,et al.  Tumours can act as adjuvants for humoral immunity , 2001, Immunology.

[70]  R. Herbert,et al.  Effect of Melatonin and Linolenic Acid on Mammary Cancer in Transgenic Mice with c-neu Breast Cancer Oncogene , 2000, Breast Cancer Research and Treatment.

[71]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[72]  A. Berns,et al.  Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. , 2000, Genes & development.

[73]  R. Kucherlapati,et al.  The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. , 2000, Cancer research.

[74]  M. Radman,et al.  HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions , 1999, Nature Genetics.

[75]  E. Buchdunger,et al.  In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. , 1999, Journal of the National Cancer Institute.

[76]  M. Vooijs,et al.  Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse , 1998, Oncogene.

[77]  Hiroyuki Miyoshi,et al.  Intestinal Tumorigenesis in Compound Mutant Mice of both Dpc4(Smad4) and Apc Genes , 1998, Cell.

[78]  C. Figdor,et al.  Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100. , 1997, Melanoma research.

[79]  R. Kucherlapati,et al.  Mutation in the Mismatch Repair Gene Msh6 Causes Cancer Susceptibility , 1997, Cell.

[80]  T. Noda,et al.  Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. , 1997, Science.

[81]  E. Jaffee,et al.  The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[82]  M Oshima,et al.  Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[83]  A. Bradley,et al.  Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. , 1994, Oncogene.

[84]  C. Croce.  Genetic approaches to the study of the molecular basis of human cancer. , 1991, Cancer research.

[85]  P. Hand,et al.  Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. , 1991, Cancer research.

[86]  W. Lee,et al.  Tumor suppressor genes: new prospects for cancer research. , 1991, Journal of the National Cancer Institute.

[87]  H. Pitot,et al.  A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. , 1990, Science.

[88]  M. Bevan,et al.  Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides , 1988, The Journal of experimental medicine.

[89]  B. Vogelstein,et al.  Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. , 1988, Cancer research.

[90]  W. Robinson,et al.  Use of differentiation inducing agents in the myelodysplastic syndrome and acute non‐lymphocytic leukemia , 1988, American journal of hematology.

[91]  Pierce Gb,et al.  Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. , 1988 .

[92]  R. Weinberg,et al.  Cellular oncogenes and multistep carcinogenesis. , 1983, Science.

[93]  T. Hesterberg,et al.  ROLE OF GENE AND CHROMOSOMAL MUTATIONS IN CELL TRANSFORMATION , 1983, Annals of the New York Academy of Sciences.

[94]  C. Bloomfield,et al.  Chromosomal abnormalities in acute lymphoblastic leukemia. , 1981, Cancer research.

[95]  M. Yi,et al.  Perturbation of Rb , p 53 and Brca 1 or Brca 2 cooperate in inducing metastatic serous epithelial ovarian cancer , 2012 .

[96]  Sun-Mi Park,et al.  CD95 promotes tumour growth , 2011, Nature.

[97]  S. Egan,et al.  Tumor and Stem Cell Biology Cooperation between Pik 3 ca and p 53 Mutations in Mouse Mammary Tumor Formation , 2011 .

[98]  Lisa L. Smith,et al.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. , 2010, Cancer research.

[99]  Katherine M Malinda,et al.  In vivo matrigel migration and angiogenesis assay. , 2009, Methods in molecular biology.

[100]  H. Koeppen,et al.  HER 2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER 2-Transgenic Mice , 2004 .

[101]  K. M. Malinda.  In vivo matrigel migration and angiogenesis assays. , 2001, Methods in molecular medicine.

[102]  G. B. Pierce,et al.  Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. , 1988, Cancer research.

[103]  J. Cowell,et al.  Double minutes and homogeneously staining regions: gene amplification in mammalian cells. , 1982, Annual review of genetics.